Efficacy and safety of cyclic pyranopterin monophosphate substitution in severe molybdenum cofactor deficiency type A: a prospective cohort study
BC Schwahn, FJ Van Spronsen, AA Belaidi, S Bowhay… - The Lancet, 2015 - thelancet.com
The Lancet, 2015•thelancet.com
Summary Background Molybdenum cofactor deficiency (MoCD) is characterised by early,
rapidly progressive postnatal encephalopathy and intractable seizures, leading to severe
disability and early death. Previous treatment attempts have been unsuccessful. After a
pioneering single treatment we now report the outcome of the complete first cohort of
patients receiving substitution treatment with cyclic pyranopterin monophosphate (cPMP), a
biosynthetic precursor of the cofactor. Methods In this observational prospective cohort …
rapidly progressive postnatal encephalopathy and intractable seizures, leading to severe
disability and early death. Previous treatment attempts have been unsuccessful. After a
pioneering single treatment we now report the outcome of the complete first cohort of
patients receiving substitution treatment with cyclic pyranopterin monophosphate (cPMP), a
biosynthetic precursor of the cofactor. Methods In this observational prospective cohort …
Background
Molybdenum cofactor deficiency (MoCD) is characterised by early, rapidly progressive postnatal encephalopathy and intractable seizures, leading to severe disability and early death. Previous treatment attempts have been unsuccessful. After a pioneering single treatment we now report the outcome of the complete first cohort of patients receiving substitution treatment with cyclic pyranopterin monophosphate (cPMP), a biosynthetic precursor of the cofactor.
Methods
In this observational prospective cohort study, newborn babies with clinical and biochemical evidence of MoCD were admitted to a compassionate-use programme at the request of their treating physicians. Intravenous cPMP (80–320 μg/kg per day) was started in neonates diagnosed with MoCD (type A and type B) following a standardised protocol. We prospectively monitored safety and efficacy in all patients exposed to cPMP.
Findings
Between June 6, 2008, and Jan 9, 2013, intravenous cPMP was started in 16 neonates diagnosed with MoCD (11 type A and five type B) and continued in eight type A patients for up to 5 years. We observed no drug-related serious adverse events after more than 6000 doses. The disease biomarkers urinary S-sulphocysteine, xanthine, and urate returned to almost normal concentrations in all type A patients within 2 days, and remained normal for up to 5 years on continued cPMP substitution. Eight patients with type A disease rapidly improved under treatment and convulsions were either completely suppressed or substantially reduced. Three patients treated early remain seizure free and show near-normal long-term development. We detected no biochemical or clinical response in patients with type B disease.
Interpretation
cPMP substitution is the first effective therapy for patients with MoCD type A and has a favourable safety profile. Restoration of molybdenum cofactor-dependent enzyme activities results in a greatly improved neurodevelopmental outcome when started sufficiently early. The possibility of MoCD type A needs to be urgently explored in every encephalopathic neonate to avoid any delay in appropriate cPMP substitution, and to maximise treatment benefit.
Funding
German Ministry of Education and Research; Orphatec/Colbourne Pharmaceuticals.
thelancet.com